|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
|---|---|
| Information provided by: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| ClinicalTrials.gov Identifier: | NCT00073203 |
Purpose
The purpose of this research study is to determine the effectiveness of 2 target doses of R228060 in comparison with placebo during 6 weeks of treatment in moderately to severely depressed adult subjects with major depressive disorder.
Approximately 488 subjects will be involved in the study.
| Condition | Intervention | Phase |
|---|---|---|
|
Major Depressive Disorder |
Drug: R228060 Drug: Placebo and Paroxetine |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Efficacy Study |
| Official Title: | A 6- Week, Randomized, Double-Blind, Parallel-Group, Active-and Placebo-Controlled Trial to Assess the Efficacy of R228060 in Adult Subjects With Major Depressive Disorder (MDD) |
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations
More Information
| Study ID Numbers: | R228060-MDD-201 |
| Study First Received: | November 17, 2003 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00073203 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Neurotransmitter Agents Depression Psychotropic Drugs Depressive Disorder, Major Depressive Disorder Paroxetine Serotonin Uptake Inhibitors |
Serotonin Behavioral Symptoms Mental Disorders Mood Disorders Antidepressive Agents, Second-Generation Antidepressive Agents |
|
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Depression Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Depressive Disorder, Major Depressive Disorder Paroxetine Serotonin Uptake Inhibitors |
Pharmacologic Actions Behavioral Symptoms Serotonin Agents Pathologic Processes Mental Disorders Therapeutic Uses Mood Disorders Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |